Multi-year agreement will provide clinical workflow software and laboratory support for GlycoKnow liquid biopsy test.
InterVenn Biosciences has partnered with Aranscia to accelerate commercialization of its GlycoKnow ovarian cancer diagnostic test through expanded clinical workflow capabilities and laboratory support services.
Under the multi-year partnership, Aranscia will provide InterVenn with software-based, electronic medical record-agnostic clinical workflow utilities through its Spesana and 2bPrecise platforms. AccessDx Laboratory, an Aranscia company, will offer logistical program support resources to facilitate delivery of diagnostic results across women’s health, oncology, and health system care settings.
“We’re pleased to be partnering with the Aranscia team in our mission to improve the care and treatment journey for all who may benefit from the insights afforded by GlycoKnow Ovarian and potential additional GlycoKnow tests in the future,” says Andrew Quong, CEO of InterVenn, in a release.
GlycoKnow Ovarian is a proprietary blood-based liquid biopsy test that helps distinguish ovarian cancer from benign pelvic masses. The test aims to identify the 80% of pelvic masses that are benign through non-invasive blood testing, potentially reducing unnecessary procedures and associated complications. InterVenn offers the test as a laboratory-developed test.
The partnership leverages Aranscia’s existing infrastructure supporting thousands of client groups, including health systems, municipalities, accountable care organizations, and multi-provider organizations. Aranscia’s portfolio includes companies with expertise in molecular diagnostics, genomics, and digital-first clinical workflows.
“We’re proud to support InterVenn’s mission to accelerate the efficiency of detection and care in the battle against ovarian cancer,” says Bryon Cipriani, CEO of Aranscia, in a release. “This partnership builds upon the foundational efforts and platform assets of the Aranscia family of companies to democratize access to the power of precision care.”
ID 409917748 © Parinda Yatha | Dreamstime.com
We Recommend for You:
